StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more
StageZero Life Sciences Ltd (SZLSF) - Total Assets
Latest total assets as of September 2024: $580.75K USD
Based on the latest financial reports, StageZero Life Sciences Ltd (SZLSF) holds total assets worth $580.75K USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
StageZero Life Sciences Ltd - Total Assets Trend (1998–2022)
This chart illustrates how StageZero Life Sciences Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
StageZero Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2022)
StageZero Life Sciences Ltd's total assets of $580.75K consist of 38.0% current assets and 62.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.2% |
| Accounts Receivable | $31.24K | 4.5% |
| Inventory | $95.62K | 13.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2022)
This chart illustrates how StageZero Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: StageZero Life Sciences Ltd's current assets represent 38.0% of total assets in 2022, a decrease from 60.1% in 1998.
- Cash Position: Cash and equivalents constituted 2.2% of total assets in 2022, down from 57.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is inventory at 13.7% of total assets.
StageZero Life Sciences Ltd Competitors by Total Assets
Key competitors of StageZero Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.47 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
StageZero Life Sciences Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - StageZero Life Sciences Ltd generates 5.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - StageZero Life Sciences Ltd is currently not profitable relative to its asset base.
StageZero Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.04 | 0.19 |
| Quick Ratio | 0.02 | 0.03 | 0.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-10.09 Million | $ -7.98 Million | $ -3.45 Million |
StageZero Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between StageZero Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.60 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -93.4% |
| Total Assets | $700.65K |
| Market Capitalization | $61.77K USD |
Valuation Analysis
Below Book Valuation: The market values StageZero Life Sciences Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: StageZero Life Sciences Ltd's assets decreased by 93.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for StageZero Life Sciences Ltd (1998–2022)
The table below shows the annual total assets of StageZero Life Sciences Ltd from 1998 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $700.65K | -93.42% |
| 2021-12-31 | $10.65 Million | +25.13% |
| 2020-12-31 | $8.51 Million | +333.01% |
| 2019-12-31 | $1.96 Million | -20.96% |
| 2018-12-31 | $2.49 Million | -7.71% |
| 2017-12-31 | $2.69 Million | -21.74% |
| 2016-12-31 | $3.44 Million | +501.57% |
| 2015-12-31 | $572.14K | -80.48% |
| 2014-12-31 | $2.93 Million | -2.09% |
| 2013-12-31 | $2.99 Million | -70.19% |
| 2012-12-31 | $10.04 Million | +146.56% |
| 2011-12-31 | $4.07 Million | -18.49% |
| 2010-12-31 | $5.00 Million | -21.45% |
| 2009-12-31 | $6.36 Million | +6.20% |
| 2008-12-31 | $5.99 Million | -68.54% |
| 2007-12-31 | $19.03 Million | -10.18% |
| 2006-12-31 | $21.19 Million | +141.43% |
| 2005-12-31 | $8.78 Million | -33.24% |
| 2004-12-31 | $13.15 Million | +109.42% |
| 2003-12-31 | $6.28 Million | +204.11% |
| 2002-12-31 | $2.06 Million | -13.97% |
| 2000-12-31 | $2.40 Million | -40.98% |
| 1999-12-31 | $4.07 Million | +2316.80% |
| 1998-12-31 | $168.21K | -- |